# Tegoprazan Phase 3 clinical trial results

> Live situation record from CLSTR: https://clstr.news/situations/tegoprazan-phase-3-clinical-trial-results
> Updated: 2026-10-16T14:30:00.000Z. Sources: 6. Developments: 2.

Clinical trial data for tegoprazan, an investigational potassium-competitive acid blocker (P-CAB), has shown positive results in treating non-erosive gastroesophageal reflux disease (NERD). 

Results from the Phase 3 TRIUMpH-NERD study, presented at the American College of Gastroenterology 2026 annual meeting, indicated that both 50mg and 100mg once-daily doses significantly increased the number of heartburn-free and regurgitation-free days in 783 American adult patients compared to a placebo. These improvements were observed from the first day of treatment and maintained through a 20-week extension period.

A post-hoc analysis regarding erosive esophagitis (EE) also received the ACG Presidential Award, demonstrating a 75.4% healing rate at week 2 for tegoprazan compared to 60.7% for lansoprazole. US partner Sebela Pharmaceuticals is currently awaiting the outcome of a New Drug Application (NDA) for the drug, which is under review by the U.S. Food and Drug Administration (FDA).

## Timeline

### 2026-10-16: Tegoprazan shows efficacy in Phase 3 NERD clinical trials

Phase 3 trial data shows tegoprazan, an investigational P-CAB, significantly improves heartburn and regurgitation symptoms in adults with non-erosive reflux disease compared to a placebo.

2 sources. https://clstr.news/cluster/tegoprazan-shows-efficacy-in-phase-3-nerd-clinical-trials

### 2026-10-11: HK inno.N's K-CAB shows positive US Phase 3 results for NERD

HK inno.N's K-CAB (tegoprazan) met primary and secondary endpoints in a US Phase 3 trial for non-erosive gastroesophageal reflux disease, strengthening its position for FDA approval.

4 sources. https://clstr.news/cluster/hk-innons-k-cab-shows-positive-us-phase-3-results-for-nerd

---
Cite as: Tegoprazan Phase 3 clinical trial results. CLSTR, https://clstr.news/situations/tegoprazan-phase-3-clinical-trial-results